PBYI Stock Risk & Deep Value Analysis

Puma Biotechnology Inc

Healthcare • Biotechnology

DVR Score

2.0

out of 10

Risk Trap

What You Need to Know About PBYI Stock

We analyzed Puma Biotechnology Inc using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran PBYI through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.

Updated Feb 13, 2026•Run Fresh Analysis →

How Risky Is PBYI Stock?

Overall Risk

Moderate

Financial Risk

Low

Market Risk

High

Competitive Risk

High

Execution Risk

Medium

Regulatory Risk

Medium

What Are the Red Flags for PBYI?

⚠
Launch of highly effective competitor drugs in HER2-positive breast cancer market
⚠
Negative clinical trial results for pipeline candidates
⚠
Significant decline in NERLYNX sales due to competitive pressure or market shifts
⚠
Adverse regulatory developments or safety concerns for NERLYNX

Unlock PBYI Red Flags & Risk Warnings

Create a free account to see the full analysis

What Does Puma Biotechnology Inc (PBYI) Do?

Market Cap

$254.48M

Sector

Healthcare

Industry

Biotechnology

Employees

172

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Visit Puma Biotechnology Inc Website

Is PBYI Stock Undervalued?

Puma Biotechnology's core asset, NERLYNX, continues to generate stable revenue within the competitive HER2-positive breast cancer market. While the company maintains financial stability and operational efficiency, there are no new material catalysts, pipeline breakthroughs, or strategic shifts that indicate a path to 10x growth within the 3-5 year timeframe. The competitive landscape remains intense, and PBYI's strategic focus appears centered on sustaining NERLYNX sales rather than pursuing transformative market expansion or disruptive innovation. This lack of an exponential growth driver or significant competitive moat limits its upside potential despite its established product.

Unlock the full AI analysis for PBYI

Get the complete DVR score, risk analysis, and more

Is PBYI Financially Healthy?

P/E Ratio

6.82

Does PBYI Have a Competitive Moat?

Moat Rating

🛡️ Narrow

Moat Trend

Eroding

Moat Sources

1 Identified

Intangible Assets/IP (patent protection for NERLYNX)

NERLYNX has patent protection, but its durability is challenged by a highly competitive landscape with drugs offering potentially superior efficacy and broader indications, limiting pricing power and market share retention over the long term. The 'niche' aspect provides some stability but little growth.

Moat Erosion Risks

•Launch of next-generation HER2-targeted therapies with superior profiles
•Expiration of key patents for NERLYNX (further out but relevant long-term)
•Increased payer pressure and competition driving down pricing

PBYI Competitive Moat Analysis

What Could Drive PBYI Stock Higher?

Near-Term (0-6 months)

•Q4 2025 Earnings Call (Estimated late February/early March 2026)
•Potential minor updates on NERLYNX label expansion studies

Medium-Term (6-18 months)

•Readouts from early-stage pipeline assets (e.g., PB272 development) - unlikely to be transformative in 18 months
•New commercial partnerships in smaller international markets

Long-Term (18+ months)

•Highly speculative: Potential acquisition by a larger pharmaceutical company seeking a niche oncology asset
•Development of a truly novel HER2 inhibitor with superior efficacy/safety (currently not apparent in pipeline)

Catalysts & Growth Drivers

Upgrade to Premium to see catalysts

What's the Bull Case for PBYI?

✓
Unexpected positive Phase 3 clinical trial data for a pipeline asset
✓
Significant M&A speculation or a definitive acquisition offer
✓
Accelerated growth in NERLYNX sales exceeding market expectations

Bull Case Analysis

See what could go right with Premium

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.

Analyze Any Stock →View Top 100 Deep Value Stocks →

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for PBYI (Puma Biotechnology Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.